Még nem toboroz
Study of the Effects of Rimonabant on Functional Recovery in Subacute Stroke Patients
NCT07941479· 2. fázis· Sinfatin S.L· Forrás
Még nem toboroz
Rimonabant for Improving Walking Ability in Patients With Chronic Stroke
NCT07913763· 2. fázis· Sinfatin S.L· Forrás
Toboroz
Evaluation of the Safety and Efficacy of Rimonabant on Cognitive impairment in patients with post-COVID-19 Syndrome.
2023-507870-42-00· 2. fázis· Sinfatin S.L.· Forrás
Toboroz
A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone
2025-524308-31-00· 2. fázis· Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.· Forrás
Még nem toboroz
Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma
2026-526352-31-00· 2. fázis· Fundacion PETHEMA· Forrás
Toboroz
Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock
NCT07583446· 2/3. fázis· Seismic Pharmaceuticals Operations LLC· Forrás
Még nem toboroz
A study that compares Depigoid Olea (a medication to treat olive pollen allergies) and placebo in patients who have a runny nose and pink and itchy eyes due to olive pollen allergy.
2026-525840-13-00· 3. fázis· LETI Pharma S.L.U.· Forrás
Toboroz
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
Grass Immunotherapy for Rhinitis and Asthma (GIRA)
2025-521736-10-00· 3. fázis· LETI Pharma S.L.U.· Forrás
Toboroz
Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES)
2025-521709-42-00· 3. fázis· LETI Pharma S.L.U.· Forrás
Toboroz
A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia older than 60 years and/or inelegible for standard induction chemotherapy
2025-523238-17-00· 2. fázis· Fundacion PETHEMA· Forrás
Toboroz
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
NCT07242547· 2. fázis· Fundación GECP· Forrás
Toboroz
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy
2025-522979-29-00· 3. fázis· Fundacion PETHEMA· Forrás
Toboroz
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás
Toboroz
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574· 2. fázis· Hoffmann-La Roche· Forrás
Még nem toboroz
Treatment for Ph-negative ALL for Adults up to 65 Years
NCT07443592· PETHEMA Foundation· Forrás
Contact: Jesús Lorenzo Algarra, Dr (principal investigator)
Fut, nem toboroz
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312· 3. fázis· Kura Oncology, Inc.· Forrás
Még nem toboroz
A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
NCT07082452· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Toboroz
Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION)
2024-519521-37-01· 2/3. fázis· Corxel Pharmaceuticals Co. Ltd.· Forrás
Toboroz
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT05691244· 3. fázis· Pharmazz, Inc.· Forrás
Toboroz
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease
2024-513035-25-00· 2. fázis· Intra-Cellular Therapies Inc.· Forrás
Toboroz
Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation
NCT06863155· Fundación EPIC· Forrás
Contact: Juan Gabriel Córdoba Soriano, MD, PhD
Toboroz
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
NCT06713837· 3. fázis· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Forrás
Fut, nem toboroz
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Fut, nem toboroz
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
NCT02205762· 2/3. fázis· St. Anna Childrens Cancer Research Institute GmbH· Forrás
Toboroz
Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism
2024-511959-18-01· 3. fázis· Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal· Forrás
Fut, nem toboroz
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma
2023-505436-35-00· 3. fázis· Lysarc· Forrás
Fut, nem toboroz
PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients
NCT06321757· Fundación EPIC· Forrás
Toboroz
A Phase 1/2 study of Enzomenib (DSP-5336) in Patients with Acute leukemia
2022-502741-10-00· 1/2. fázis· Sumitomo Pharma America Inc.· Forrás
Toboroz
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
NCT07159750· Hospital Universitari Vall d'Hebron Research Institute· Forrás
Contact: Almudena Layos-Romero
Fut, nem toboroz
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial
NCT05599061· Fundación EPIC· Forrás
Toboroz
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
NCT05558319· 3. fázis· PETHEMA Foundation· Forrás
Contact: Irene Gómez Catalán
Fut, nem toboroz
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT
2024-517008-12-00· 3. fázis· Fundacion PETHEMA· Forrás
Toboroz
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555· 1/2. fázis· Sumitomo Pharma America, Inc.· Forrás
Contact: Jesus Lorenzo Algarra, MD
Toboroz
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
NCT05283356· 4. fázis· Fundacin Biomedica Galicia Sur· Forrás
Fut, nem toboroz
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Randomised, double-blind, placebo-controlled study to evaluate the effect of metformin, an AMPK activator, on cognitive measures of progression in Huntington's disease patients.
2024-518875-73-00· 3. fázis· IIS La Fe· Forrás
Toboroz
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216· 2/3. fázis· DiaMedica Therapeutics Inc· Forrás
Fut, nem toboroz
ANGiographic Evaluation of Left Main Coronary Artery INtErvention
NCT04604197· Fundación EPIC· Forrás
Fut, nem toboroz
Concordance Between FFR and iFR for the Assessment of Intermediate Lesions in the Left Main Coronary Artery. A Prospective Validation of a Default Value for iFR
NCT03767621· Fundación EPIC· Forrás
Fut, nem toboroz
Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 years old, in good general health and newly diagnosed multiple myeloma.
2024-516905-22-00· 3. fázis· Fundacion PETHEMA· Forrás
Toboroz
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
NCT02832245· Manuel Monreal· Forrás
Contact: María Melero